• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Oncotarget: Loss of p16 and high Ki67 labeling index is associated with poor outcome

Bioengineer by Bioengineer
May 6, 2020
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Oncotarget Volume 11, Issue 12 reported that the p16 tumor suppressor is coded by CDKN2A and plays an important role during carcinogenesis and tumor progression in numerous tumor entities

IMAGE

Credit: Correspondence to – Nathaniel Melling – [email protected]

Oncotarget Volume 11, Issue 12 reported that the p16 tumor suppressor is coded by CDKN2A and plays an important role during carcinogenesis and tumor progression in numerous tumor entities.

P16 positivity was found in 30.2% of AC and 13.9% of SCC and CDKN2A deletion in 32.1% of AC and 33.5% of SCC. In AC Ki67 positivity was associated with high tumor stage, presence of lymph node metastasis, high UICC stage and poor grading.

Dr. Nathaniel Melling from the Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany said, “Despite recent advances in the management of the disease, esophageal cancer (EC) is the sixth most lethal malignant disease with nearly half a million novel cases and over 400,000 deaths worldwide.“

“Despite recent advances in the management of the disease, esophageal cancer (EC) is the sixth most lethal malignant disease with nearly half a million novel cases and over 400,000 deaths worldwide.”

– Dr. Nathaniel Melling, Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf

The p16 tumor suppressor has been reported to play a pivotal role in cancer, since it inhibits cyclin-dependent kinases 4 and 6 at the G1 to S-phase transition of the cell cycle and thus prevents phosphorylation of the retinoblastoma protein.

P16 plays an important role during carcinogenesis and tumor progression in numerous tumor entities including cancers of the colon, liver, gallbladder, and skin.

Its expression is associated with unfavorable or favorable tumor phenotype depending on the analyzed tumor entity.

To elucidate the potential role of both p16 expression and CDKN2A deletion as prognostic biomarkers the authors examined our preexisting EC tissue microarray built from tumor samples of more than 690 individual EC patients.

The Melling Research Team concluded in their Oncotarget Research Paper, “the results of our study show that loss of p16 expression – but not CDKN2A deletion – is linked to shortened overall survival in patients with esophageal AC. Furthermore, strong Ki67LI is an independent prognosticator of poor survival in AC. Rare homozygous 9p21 deletions can be considered as catastrophic events leading to complete loss of p16 expression.“

###

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.27507

Full text – https://www.oncotarget.com/article/27507/text/

Correspondence to – Nathaniel Melling – [email protected]

Keywords –
p16,
9p21,
esophageal cancer,
TMA,
prognosis

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.impactjournals.com/ or connect with @ImpactJrnls

Media Contact

[email protected]
18009220957×105

Media Contact
Ryan James Jessup
[email protected]

Original Source

https://www.oncotarget.com/news/pr/loss-of-p16-and-high-ki67-labeling-index-is-associated-with-poor-outcome/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27507

Tags: cancerCarcinogensMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Bridging Two Frontiers: Mitochondria and Microbiota — Targeting Extracellular Vesicles in 2025 to Unlock Revolutionary Medical Pathways

Bridging Two Frontiers: Mitochondria and Microbiota — Targeting Extracellular Vesicles in 2025 to Unlock Revolutionary Medical Pathways

October 7, 2025

Unveiling Oral Health Neglect in Iranian Seniors

October 7, 2025

Insufficient NNMT Disrupts Implantation via H3K9me3 Pathway

October 7, 2025

AI Diagnostic System Performance Evaluation in China

October 7, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    936 shares
    Share 374 Tweet 234
  • New Study Reveals the Science Behind Exercise and Weight Loss

    99 shares
    Share 40 Tweet 25
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    95 shares
    Share 38 Tweet 24
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    77 shares
    Share 31 Tweet 19

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Natural ‘Battery’ of Soil Bacteria and Minerals Dismantles Antibiotics in Darkness

Rice University Unveils Second Cohort of Chevron Energy Graduate Fellows

Cutting-Edge Imaging Technology Set to Revolutionize Skin Cancer Diagnosis and Treatment

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.